The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

Completed · Phase 2

Conditions studied: Acute Kidney Injury

In brief

The purpose of this study is to determine if the use of erythropoietin when used in high dose during acute kidney injury can decrease the number of days of kidney injury.

Key facts

Study ID

NCT03102021

Run by

North Texas Veterans Healthcare System

People needed

25

Starts

2006-03-01

Expected to finish

2013-06-01

Last updated by the study team

2017-04-05

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age equal or greater than 21 yo
• acute neprhotoxic or ischemic kidney injury, acute tubular necrosis

You may not qualify if…

• no active or current malignancies
• not actively receiveing epo
• GFR less than 60 ml/min
• unable to provide informed consent
• contraindication to erythropoietin use

Where it is running

• Dallas VAMC — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.